TrialBMC musculoskeletal disorders2008

A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.

Kirstin Stricker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.